companiesCompany
Exelixis
Exelixis makes cabozantinib (Cabometyx), used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.
Cabozantinib is approved in RCC (alone and with nivolumab), HCC after sorafenib (CELESTIAL), differentiated thyroid cancer, and advanced pancreatic and extra-pancreatic neuroendocrine tumours (CABINET, March 2025). Next-generation TKI zanzalintinib is in phase 3 in colorectal cancer and NETs.